Navigation Links
Cell Therapeutics Reports Second Quarter 2013 Financial Results
Date:7/31/2013

SEATTLE, July 31, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the second quarter and six months ended June 30, 2013.

"The second quarter was highlighted by the substantial progress we made in our reimbursement discussions for PIXUVRI® (pixantrone) in Europe, specifically in the UK and Italy," said James Bianco, M.D., President and CEO of CTI. "In particular, we look forward to our planned launch of PIXUVRI in Italy, where AIFA granted market access to bring this new approved therapy to patients with aggressive B-cell non-Hodgkin lymphoma (NHL) who have failed 2 or 3 prior regimens.  In addition, PERSIST-1, our randomized Phase 3 clinical trial designed to evaluate the safety and efficacy of pacritinib compared to best available therapy, excluding JAK inhibitors, continues to enroll patients with myelofibrosis.  A second planned Phase 3 trial is on track to initiate later this year."

Second Quarter 2013 and Recent HighlightsPIXUVRI® (pixantrone) Commercial:  Reimbursement Progress in Top European Markets

  • Received notice in July that market access in Italy was granted by the Italian Medicines Agency (AIFA) for PIXUVRI as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell NHL (patients with aggressive B-cell NHL who failed 2 or 3 prior lines of therapy). 
  • Received notice in July that the UK's Department of Health approved CTI's patient access scheme relating to PIXUVRI.  An independent appraisal committee of the National Institute for Health and Clinical Excellence (NICE) is scheduled to consider the new evidence on the cost effectiveness of PIXVURI at its meeting in September 2013.
  • Announced in May that Germany's Federal Joint Committee (G-BA) reported that additional benefit could not be determined for PIXUVRI versus the c
    '/>"/>

  • SOURCE Cell Therapeutics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
    2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
    3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
    4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
    5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
    6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
    7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
    8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
    9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
    10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
    11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2014)... , July 29, 2014  Landauer, Inc. (NYSE: ... and environmental radiation measurement and monitoring, outsourced medical physics ... financial results for the fiscal third quarter 2014 after ... The Company will host a conference call ... a.m. Central Time (10 a.m. Eastern Time). Investors may ...
    (Date:7/29/2014)... WASHINGTON , July 29, 2014 New ... in Medicare Part D by a projected $2.9 to ... by the actuarial firm Milliman released today by the ... Part D premiums could increase by as much as ... hepatitis C drugs, including Sovaldi and Olysio. ...
    (Date:7/29/2014)... July 29, 2014 Numotion,s Board of Directors has ... will be the company,s new Chief Executive Officer. ... career at GE where he worked primarily for GE Healthcare ... to over $5 billion. His most recent position was as ... "I am thrilled to join Numotion," said Mike ...
    Breaking Medicine Technology:Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2014 Results 2New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Numotion Names Mike Swinford CEO 2
    ... 3, 2011 Nonin Medical, Inc., the inventor of ... a leader in noninvasive physiological monitoring, announced the worldwide ... Pulse Oximeter for medical monitoring manufacturers. ... wired pulse oximeter will provide a new level of ...
    ... Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR ) ... Senior Vice President of Research and Development, Cynthia Schwalm ... M.D., as Senior Vice President of Pharmacovigilance. These newly ... the Company prepares for the potential launch of its ...
    Cached Medicine Technology:Nonin Medical Launches Low Power Xpod®, Model 3012LP, OEM Pulse Oximeter Globally 2Optimer Pharmaceuticals Expands Senior Management Team 2Optimer Pharmaceuticals Expands Senior Management Team 3Optimer Pharmaceuticals Expands Senior Management Team 4Optimer Pharmaceuticals Expands Senior Management Team 5
    (Date:7/30/2014)... The Diabetes Daily Grind had its beginnings ... Ryan Fightmaster hope to gain attention for the website ... 26th of this year, Clour and Fightmaster started this ... diabetic life. By sharing stories on their lessons ... other diabetics will find ways to live with their ...
    (Date:7/30/2014)... According to the Nasal Polyps Treatment Miracle book review recently ... people how to cure their nasal polyps permanently ... horrible truth about conventional treatments for nasal polyps. , ... will learn how to prevent symptoms related to nasal ... Nasal Polyps Treatment Miracle, as it is reviewed now by ...
    (Date:7/30/2014)... The San Diego personal injury lawyers of The ... they are now offering free case reviews for individuals that ... , “Symptoms of asbestos exposure can take years to develop, ... years ago may just now be suffering from the ill ... Melinda J. Helbock A.P.C. “We want people to know that ...
    (Date:7/30/2014)... (PRWEB) July 30, 2014 Nuanced Media, a ... announce the release of the Medical Web Design Trends of ... of research done across multiple agencies and the medical web ... are constantly changing as the industry grows. Therefore it is ... of ideas that consumers enjoy most. New trends are defined ...
    (Date:7/29/2014)... 30, 2014 Saint Luke’s Medical ... awarded the Patient-Centered Medical Home 2011 Level 3 ... for Quality Assurance. Only one out of four ... Level 2, or Level 3 recognition. , Patients ... Medical Home report faster access to their doctors, ...
    Breaking Medicine News(10 mins):Health News:Strangers Come Together to Form Diabetes Website: Real Messages of Hope and Inspiration 2Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 2Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 3Health News:The Law Office of Melinda J. Helbock A.P.C. Offers Case Evaluations for Possible Asbestos Claims 2Health News:Nuanced Media Releases "Medical Web Design Trends of 2014" Article 2Health News:Saint Luke’s Medical Group Awarded Patient-Centered Medical Home 2011 Level 3 Recognition 2
    ... of the disease among those vaccinated were no higher ... (HealthDay News) -- Rates of a rare neurodegenerative disease, ... last year were no higher than among the general ... syndrome were noted after widespread swine flu vaccination in ...
    ... April 13, 2010 Allergies have become a widespread ... are all increasingly prevalent. The reason? Excessive cleanliness is ... at the Universit de Montral Faculty of Medicine. ... pollution, processed foods, stress, tobacco use, etc. Yet our ...
    ... 2010) The human mouth is home to an estimated ... moist environment, along with hard tooth surfaces and soft tissues, ... of these bacteria are harmful and can form a film ... eventually more severe kinds of gum disease. Toothpaste ...
    ... ... features and prices of March special SEO offers, SEO-Peace.com management is pleased to extend its ... features to the client base. , ... Gurgaon, India (PRWEB) April 13, 2010 -- With SEO industry getting more and more ...
    ... , ... 1 out of every 6 men in the United States (1 in 3 in the ... against prostate cancer by registering for Little Red Door,s Unite 2 Fight Race Against Prostate ... Indianapolis, IN (PRWEB) ...
    ... with Williams syndrome have no social fear and appear ... 13 (HealthDay News) -- Children with a rare ... and with it, racial prejudice, a new study shows. ... the root cause of racial stereotyping. , French and ...
    Cached Medicine News:Health News:Guillain-Barre Syndrome Very Rare After H1N1 Vaccine 2Health News:Guillain-Barre Syndrome Very Rare After H1N1 Vaccine 3Health News:Why are allergies increasing? 2Health News:Give dirty mouths a brush 2Health News:SEO-Peace.com Extends The March Special SEO Special Offers And Revise Many Services 2Health News:Registration Now Open for Little Red Door's Unite 2 Fight Race Against Prostate Cancer Saturday, July 10, 2010 2Health News:Kids With Rare Condition Lack Racial Prejudice 2
    Molt periosteal elevator #9, 18.5 cm, 7-1/4"....
    Periosteal elevator #9, 18 cm, 7"....
    Full curve periosteal elevator - cervical - sharp, round tip, length 184 mm (7 1/4")....
    ... The Frontier Anterior Deformity System ... Kass, Moss Miami, and Isola ... thoracoscopic procedures to deliver unsurpassed versatility, ... the highest level of versatility for ...
    Medicine Products: